.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market.The Eli Lilly-partnered biotech expect to provide on the Nasdaq under the icon “BIOA,” depending on to records submitted with the Securities and Exchange Compensation. The business has not publicly shared an anticipated monetary amount for the offering.The clinical-stage provider promotes lead prospect azelaprag, an orally provided small particle slated to enter into stage 2 testing in combo along with semaglutide– offered through Novo Nordisk under brand name Wegovy for weight management– in the first one-half of next year. Semaglutide is actually also offered as Ozempic as well as Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is designed to mix properly with GLP-1 drugs, enhancing effective weight loss while keeping muscle mass. The investigational medicine was found to become well-tolerated among 265 people around eight period 1 tests, according to BioAge.Recently, BioAge achieved the help of Lilly to manage a test mixing azelaprag with the Huge Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetic issues as Mounjaro and also Zepbound for fat loss. The companions are actually currently performing a period 2 test of azelaprag and tirzepatide, along with topline outcomes expected in the third quarter of 2025.The biotech is actually additionally organizing a blood insulin sensitivity proof-of-concept test evaluating azelaprag as a monotherapy in the very first fifty percent of following year to support possible evidence growth.
On top of that, the firm plans to inquire the FDA for authorization in the 2nd one-half of 2025 to release individual testing for an NLRP3 inhibitor targeting metabolic ailments and neuroinflammation.BioAge’s expected transfer to the public market adheres to a small uptick in planned biotech IPOs from Bicara Rehabs and also Zenas Biopharma. Zooming out, the recent IPO yard is actually a “mixed picture,” with high quality providers still debuting on the public markets, just in lowered numbers, depending on to PitchBook.